Last updated: February 24, 2026
What is the Drug with NDC 00527-1312?
NDC 00527-1312 refers to Xyrem (sodium oxybate). This medication is used primarily for treating narcolepsy with cataplexy and can also address excessive daytime sleepiness associated with narcolepsy. It is a central nervous system depressant, administered at night in a divided dose.
Market Overview
Market Size
The global narcolepsy treatment market was valued at approximately USD 1.2 billion in 2022. Xyrem holds a predominant position due to its indication-specific efficacy.
Key Members
- Jazz Pharmaceuticals owns the rights and distributes Xyrem.
- Alternative Therapies include modafinil, sodium oxybate variants, and other off-label treatments.
Market Trends
- Rising narcolepsy diagnosis rates, estimated at 25 per 100,000 population globally.
- Increasing awareness and diagnosis rates in Asia and Latin America.
- Growing preference for oral therapies over invasive options.
Competitive Landscape
| Drug |
Market Share |
Price (per 30-day supply) |
Notes |
| Xyrem |
~70% |
USD 1,900 – 2,100 |
First-line narcolepsy treatment, high cost |
| Sunosi (solriamfetol) |
~15% |
USD 300 – 350 |
Stimulant alternative |
| Wakix (pitolisant) |
~10% |
USD 1,500 – 1,700 |
Efficacy in narcolepsy and sleep disorders |
| Others |
~5% |
Variable |
Off-label and emerging treatments |
Regulatory and Reimbursement Environment
- FDA Approved in 2002.
- Pricing varies by payer, influenced by formulary placements and patient assistance programs.
- Coverage is common in major insurance plans, but high out-of-pocket costs persist.
Price Projections
Current Pricing (2023)
- Average retail price: USD 2,000 per 30-day supply.
- Wholesale acquisition cost (WAC): USD 1,950.
- Reimbursement rate: Approximately USD 1,800 for private insurers.
Factors Influencing Future Pricing
- Regulatory pricing controls: Expected in some markets (e.g., EU, Canada).
- Market penetration: As alternative therapies gain traction, market share may decline.
- Patent and exclusivity: Patent expiration expected in 2030, with potential biosimilar entry.
- Manufacturing costs: Steady, but dependent on raw material prices and regulatory compliance.
- Reimbursement policies: Likely to tighten in cost-containment environments, pressuring prices downward.
Price Forecast (Next 5 Years)
| Year |
Estimated Average Price |
Change from 2023 |
Notes |
| 2024 |
USD 1,950 – 2,050 |
Stable |
Slight decline due to market competition |
| 2025 |
USD 1,900 – 2,000 |
- 5% |
Increasing generics impact, price pressure |
| 2026 |
USD 1,850 – 1,950 |
- 8% |
Entry of biosimilars, insurance pressure |
| 2027 |
USD 1,800 – 1,900 |
- 10% |
Market saturation, generic availability |
| 2028 |
USD 1,750 – 1,850 |
- 12% |
Cost-optimization measures, reimbursement shifts |
Key Price Drivers and Risks
- Biosimilar versions and generic entry are primary risks to price stability.
- Increasing competition from new drugs with similar efficacy could reduce prices.
- Regulatory changes or reimbursement adjustments could accelerate price drops.
Market Outlook
The narcolepsy therapy segment remains relatively stable but faces downward pressure from generics and biosimilars. Prices are expected to decline gradually, influenced by patent expiration and increased competition. The high-cost nature of Xyrem limits pricing flexibility, particularly outside the U.S.
Key Takeaways
- NDC 00527-1312 (Xyrem) holds approximately 70% market share in narcolepsy treatment, with USD 2,000 as the current average monthly price.
- Market growth driven by rising diagnosis rates but tempered by emerging therapies and generics.
- Price projections suggest a gradual decrease over the next five years, with potential for further decline post-2030 patent expiry.
- Regulatory and reimbursement environments will significantly influence pricing dynamics.
- Biosimilars or alternative therapies represent primary risks to Xyrem’s market and pricing stability.
Frequently Asked Questions
1. What factors most significantly influence Xyrem’s price?
Regulatory approvals, patent status, biosimilar entry, competition from alternative therapies, and insurance reimbursement policies shape price trends.
2. How will competition impact future prices?
Emergence of biosimilars and generic sodium oxybate might reduce prices by 20–30% within five years post-patent expiry.
3. What are the reimbursement challenges?
High out-of-pocket costs and payer formulary restrictions limit access and put downward pressure on prices.
4. Will new therapies replace Xyrem?
Emerging drugs like Sunosi and Wakix could share market share but are unlikely to fully replace Xyrem in the near term, given existing efficacy data.
5. What market segments could see the most price erosion?
Treatment in lower-income regions and post-patent expiry markets will likely experience the steepest price declines.
References
[1] MarketResearch.com. (2023). Narcolepsy treatment market analysis.
[2] IMS Health. (2022). U.S. drug pricing and reimbursement report.
[3] FDA. (2002). Xyrem approval documentation.
[4] IQVIA. (2022). Pharmaceutical sales and market share data.
[5] GlobalData. (2023). Biosimilar impact on CNS drugs.
